Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells

被引:225
作者
Corradini, P [1 ]
Dodero, A [1 ]
Zallio, F [1 ]
Caracciolo, D [1 ]
Casini, M [1 ]
Bregni, M [1 ]
Narni, F [1 ]
Patriarca, F [1 ]
Boccadoro, M [1 ]
Benedetti, F [1 ]
Rambaldi, A [1 ]
Gianni, AM [1 ]
Tarella, C [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, Div Hematol Bone Marrow Transplantat, I-20133 Milan, Italy
关键词
D O I
10.1200/JCO.2004.12.050
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of malignancies characterized by a poor prognosis. We performed a pilot study to investigate the role of reduced-intensity conditioning (RIC) followed by allogeneic stem-cell transplantation in relapsed or refractory PTCLs. Patients and Methods. We have conducted a phase II trial on 17 patients receiving salvage chemotherapy followed by RIC and allogeneic transplantation of hematopoietic cells. The RIC regimen consisted of thiotepa, fludarabine, and cyclophosphamide. The acute graft-versus-host disease prophylaxis consisted of cyslosporine and short course methotrexate. Results. Patients had a median age of 41 years (range, 23 to 60 years). Two patients were primary chemorefractory, and 15 had relapsed disease; eight patients (47%) had a disease relapse after an autologous transplantation. After a median follow-up of 28 months from the day of study entry (range, 3 to 57 months), 14 of 17 patients were alive (12 in complete remission, one in partial remission, and one with stable disease), two died as a result of progressive disease, and one died as a result of sepsis concomitant to acute graft-versus-host disease. The estimated 3-year overall and progression-free survival rates were 81% (95% Cl, 62% to 100%) and 64% (95% Cl, 39% to 89%), respectively. The estimated probability of nonrelapse mortality at 2 years was 6% (95% Cl, 1% to 17%). Donor lymphocyte infusions induced a response in two patients progressing after allografting. Conclusion. RIC followed by allogeneic stem-cell transplantation is feasible, has a low treatment-related mortality, and seems to be a promising salvage treatment for relapsed PTCL. These findings suggest that the existence of a graft-versus-T-cell lymphoma effect. (C) 2004 by American Society of Clinical Oncology.
引用
收藏
页码:2172 / 2176
页数:5
相关论文
共 16 条
[1]   Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies [J].
Branson, K ;
Chopra, R ;
Kottaridis, PD ;
McQuaker, G ;
Parker, A ;
Schey, S ;
Chakraverty, RK ;
Craddock, C ;
Milligan, DW ;
Pettengell, R ;
Marsh, JCW ;
Linch, DC ;
Goldstone, AH ;
Williams, CD ;
Mackinnon, S .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) :4022-4031
[2]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[3]   Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies [J].
Corradini, P ;
Tarella, C ;
Olivieri, A ;
Gianni, AM ;
Voena, C ;
Zallio, F ;
Ladetto, M ;
Falda, M ;
Lucesole, M ;
Dodero, A ;
Ciceri, F ;
Benedetti, F ;
Rambaldi, A ;
Sajeva, MR ;
Tresoldi, M ;
Pileri, A ;
Bordignon, C ;
Bregni, M .
BLOOD, 2002, 99 (01) :75-82
[4]  
Dhedin N, 1999, BRIT J HAEMATOL, V107, P154
[5]  
Gisselbrecht C, 1998, BLOOD, V92, P76
[6]  
HARRIS NL, 1994, BLOOD, V84, P1361
[7]  
JONES RJ, 1991, BLOOD, V77, P649
[8]   Transplant-lite:: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies [J].
Khouri, IF ;
Keating, M ;
Körbling, M ;
Przepiorka, D ;
Anderlini, P ;
O'Brien, S ;
Giralt, S ;
Ippoliti, C ;
von Wolff, B ;
Gajewski, J ;
Donato, M ;
Claxton, D ;
Ueno, N ;
Andersson, B ;
Gee, A ;
Champlin, R .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2817-2824
[9]  
Kottaridis PD, 2000, BLOOD, V96, P2419
[10]   Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects [J].
McSweeney, PA ;
Niederwieser, D ;
Shizuru, JA ;
Sandmaier, BM ;
Molina, AJ ;
Maloney, DG ;
Chauncey, TR ;
Gooley, TA ;
Hegenbart, U ;
Nash, RA ;
Radich, J ;
Wagner, JL ;
Minor, S ;
Appelbaum, FR ;
Bensinger, WI ;
Bryant, E ;
Flowers, MED ;
Georges, GE ;
Grumet, FC ;
Kiem, HP ;
Torok-Storb, B ;
Yu, G ;
Blume, KG ;
Storb, RF .
BLOOD, 2001, 97 (11) :3390-3400